Exclusive Summary

• **Regulatory Acceleration via ICH Standards**: Leverage 'Clinical in China' (NMPA is an ICH member) data to support and expedite registration in emerging markets like Southeast Asia, LATAM, and MENA.
• **Strategic Timing for Patent Cliffs**: Target markets where originator patents are expiring; the current clinical status aligns with regulatory timelines to enable 'Day 1 Launch' opportunities for partners.
• **Cost Competitiveness via Vertical Integration**: Utilize the advantages of China's integrated API-to-FDF supply chain to offer superior pricing structures and de-risk the partner's R&D via the licensing model.

Asset Materials

Contact Us for Full Materials